Last reviewed · How we verify
Thienopyridine (open-label)
Thienopyridine (open-label) is a P2Y12 receptor antagonist / Antiplatelet agent Small molecule drug developed by VA Office of Research and Development. It is currently FDA-approved for Acute coronary syndrome, Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of cardiovascular events.
Thienopyridines inhibit platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Darexaban is a small molecule with an unknown mechanism of action, as per ChEMBL. It has been studied in clinical trials for its interaction with Acetyl Salicylic Acid (Aspirin) and Clopidogrel in conditions such as ischemic stroke, drug-eluting stents, and percutaneous coronary intervention.
At a glance
| Generic name | Thienopyridine (open-label) |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | P2Y12 receptor antagonist / Antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Thienopyridines are antiplatelet agents that irreversibly bind to the P2Y12 receptor, preventing adenosine diphosphate (ADP)-induced platelet activation and aggregation. This mechanism reduces thrombotic events by inhibiting platelet clumping and clot formation. They are commonly used to prevent stent thrombosis and reduce cardiovascular events in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome
- Prevention of stent thrombosis following percutaneous coronary intervention
- Secondary prevention of cardiovascular events
Common side effects
- Bleeding
- Thrombotic thrombocytopenic purpura (TTP)
- Neutropenia
- Gastrointestinal bleeding
Key clinical trials
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Acetyl-leucine in Post-stroke Ataxia (PHASE3)
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation (NA)
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD (NA)
- Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention (PHASE4)
- Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thienopyridine (open-label) CI brief — competitive landscape report
- Thienopyridine (open-label) updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Thienopyridine (open-label)
What is Thienopyridine (open-label)?
How does Thienopyridine (open-label) work?
What is Thienopyridine (open-label) used for?
Who makes Thienopyridine (open-label)?
What drug class is Thienopyridine (open-label) in?
What development phase is Thienopyridine (open-label) in?
What are the side effects of Thienopyridine (open-label)?
What does Thienopyridine (open-label) target?
Related
- Drug class: All P2Y12 receptor antagonist / Antiplatelet agent drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: VA Office of Research and Development — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Prevention of stent thrombosis following percutaneous coronary intervention
- Indication: Drugs for Secondary prevention of cardiovascular events
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing